Resumen
β-blockade has a therapeutic role across the continuum of patients with heart failure (HF), with a demonstrated mortality benefit in stage II and III HF. Concerns regarding initiation and uptitration linger as patients with resting bradycardia, pulmonary, or vascular disease are often unnecessarily excluded from receiving therapy. We will review the risk data on β-blockade and offer therapeutic strategies to help overcome residual barriers to the initiation and uptitration of this important therapy in patients with HF.
| Idioma original | English (US) |
|---|---|
| Páginas (desde-hasta) | 110-116 |
| Número de páginas | 7 |
| Publicación | Current Heart Failure Reports |
| Volumen | 4 |
| N.º | 2 |
| DOI | |
| Estado | Published - jun 2007 |
| Publicado de forma externa | Sí |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
- Emergency Medicine
Huella
Profundice en los temas de investigación de 'Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure'. En conjunto forman una huella única.Citar esto
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS